Improving Management of Locally Advanced and Metastatic CSCC and MBC

 

Jointly provided by Postgraduate Institute for Medicine and DKBMed.

 

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc, and Sanofi.

 

Release date: October 25, 2021

Expiration date: December 31, 2022

Estimated time to complete activity: 3.0 hours

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

 

 

Target Audience

This activity is intended for oncologists, dermatologists and others engaged in the care of patients with nonmelanoma skin cancer.

 

Educational Objectives

After completing this activity, the participant should be better able to:

• Identify patients at high risk for for mBCC and la/mCSCC in practice

• Assess advantages of multiple models of screening and staging (AJCC, BWH, etc.) for NMSC in immunosuppressed and other patients at elevated risk

• Demonstrate effective shared decision-making via role play about treatment selection for patients with mBCC and la/mCSCC

Faculty

Vishal Anil Patel, MD, FAAD, FACMS
Assistant Professor of Dermatology & Oncology
George Washington University School of Medicine & Health Sciences
Washington, DC

 

Anokhi Jambusaria-Pahlajani, MD
Assistant Professor
The University of Texas at Austin
Dell Medical School
Austin, TX

 

Saliesh Konda, MD, FAAD, FACMS
Medical Director & Clinical Associate Professor
University of Florida
Department of Dermatology
College of Medicine
Gainesville, FL

 

Anthony M. Rossi MD, FAAD
Assistant Attending, Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell Medical College
Assistant Attending, New York Presbyterian Hospital
Memorial Sloan Kettering Cancer Center
New York, NY

 

Emily S. Ruiz, MD, MPH
Director of the High Risk Skin Cancer Clinic
Brigham and Women's Hospital
Boston, MA

 

Emily Hoffman Smith, MD, FAAD
Assistant Professor of Clinical Dermatology and Dermatopathology
Department of Dermatology
University of Missouri
Columbia, MO

 

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

 

Vishal Anil Patel, MD, FAAD, FACMS

Salary from George Washington Medical Faculty Associates

Consulting Fees from Regeneron, Sanofi, Almirall

Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents from Regeneron, Sanofi, Almirall

Ownership Interest less than 5% from Science 37, Inc, Lazarus AI

 

Anokhi Jambusaria-Pahlajani, MD

Consulting Fees from Regeneron

 

Saliesh Konda MD, FAAD, FACMS

Dr. Konda has nothing to disclose.

 

Anthony M. Rossi MD, FAAD

Salary from MSKCC

Consulting Fees from Almirall, Mavig, (travel), Merz, Dynamed, Canfield Scientific, Allergan Inc, Evolus, Biofrontera, Quantia MD, Lam Therapeutics, Regeneron, Cutera,  Skinfix, L’oreal (travel)

Contracted Research from Biofrontera, Leopharma, Regen Labs

Ownership Interest less than 5% from DAR companies

 

Emily S. Ruiz, MD, MPH

Salary from Brigham and Women's Hospital

Consulting Fees from Leo Pharma, and Checkpoint Therapeutics, Sanofi, Pellepharm Inc, and Jounce

Other: Regeneron (PI)

 

Emily Hoffman Smith, MD, FAAD

Consulting Fees from Castle Biosciences

Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents from Association of Community Cancer Centers

 

The PIM planners and others have nothing to disclose. The DKBMed planners and others have nothing to disclose.

 

Method of Participation and Request for Credit

In order to claim the maximum amount of credit available (3.0 AMA PRA Category 1 Credits™) you must complete the following, including all pre and final assessments:

Self-Study Module 1 – 0.75 credits

Self-Study Module 2 - 0.75 credits

Live Group Session 1 - 0.5 credits

Live Group Session 2 - 0.5 credits

Group Task - 0.5 credits

Total credit amount - 3.0 credit hours

 

Joint Accreditation Statement

 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBMed.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.